Hung-Ying Kao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hung-Ying Kao has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Sichun Yang
Case Comprehensive Cancer Center and Department of Nutrition, School of Medicine, Case Western Reserve University; Cleveland, OH 44106, USA
14 shared publications Yu Liu
From the Department of Biochemistry and
13 shared publications- Zhenghao Liu
Department of Biochemistry and Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
12 shared publications - Donald Patrick McDonnell
Duke University School of Medicine, Durham, North Carolina
11 shared publications - Li-Sheng Geng
Beihang University
11 shared publications - Ruth A. Keri
Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
11 shared publications
Latest Publications
- Open Access
- 8 June 2026
- Published by Springer Nature in Cell Death & Differentiation
A PML1-CCL5-PI3K/MAPK feedback loop governs survival of endocrine-resistant breast cancer cells
The mechanisms that mediate endocrine therapy resistance remain incompletely understood. We identified promyelocytic leukemia protein isoform 1 (PML1) as a central node of this resistance. We established a PML1 gene signature that strongly correlates with PI3K, MAPK, and endocrine resistance signatures across multiple patient cohorts, predicting poor clinical outcomes. Mechanistically, PML1 promotes a self-reinforcing survival circuit by inducing the expression of CCL5 and HBEGF, which activate PI3K and MAPK signaling in an autocrine/paracrine manner. Reciprocally, ERK activation stabilizes PML1 protein, whereas activated mTOR increases PML1 protein synthesis, thereby establishing a positive feedback loop that sustains cancer cell survival under therapeutic pressure. Paradoxically, selective ER degraders (SERDs) and modulators (SERMs) induce PML1 protein accumulation. Fulvestrant, a SERD, while inducing ER protein degradation, rapidly activates PI3K and MAPK pathways, driving PML1 protein accumulation. Consistently, we observed an inverse relationship between ER and PML protein levels. In therapy-sensitive wild-type ER cells with low basal PML1 levels and PI3K/MAPK activity, fulvestrant’s ER-suppressive effects overcome drug-induced elevated PML1 and PI3K/MAPK activity, thereby maintaining therapeutic efficacy. In contrast, in therapy-resistant ER Y537S mutant cells or cells with PML gene amplification, fulvestrant-mediated amplification of constitutively hyperactive PML1-PI3K/MAPK feedback loops dominates over cytotoxic effects, resulting in enhanced cell survival. Notably, reducing PML1 levels through knockdown or arsenic trioxide (ATO), an FDA-approved PML1 degrader, disrupts this resistance circuit and restores endocrine sensitivity. Treatment of ATO resensitizes ER Y537S-bearing resistant tumors to endocrine therapy in xenograft models. These findings establish PML1 as a central hub of resistance, linking ER signaling to the activation of the PI3K/MAPK survival pathway.
- 8 June 2026
- Published by Springer Nature in Cell Death & Differentiation
Open AccessA PML1-CCL5-PI3K/MAPK feedback loop governs survival of endocrine-resistant breast cancer cells
The mechanisms that mediate endocrine therapy resistance remain incompletely understood. We identified promyelocytic leukemia protein isoform 1 (PML1) as a central node of this resistance. We established a PML1 gene signature that strongly correlates with PI3K, MAPK, and endocrine resistance signatures across multiple patient cohorts, predicting poor clinical outcomes. Mechanistically, PML1 promotes a self-reinforcing survival circuit by inducing the expression of CCL5 and HBEGF, which activate PI3K and MAPK signaling in an autocrine/paracrine manner. Reciprocally, ERK activation stabilizes PML1 protein, whereas activated mTOR increases PML1 protein synthesis, thereby establishing a positive feedback loop that sustains cancer cell survival under therapeutic pressure. Paradoxically, selective ER degraders (SERDs) and modulators (SERMs) induce PML1 protein accumulation. Fulvestrant, a SERD, while inducing ER protein degradation, rapidly activates PI3K and MAPK pathways, driving PML1 protein accumulation. Consistently, we observed an inverse relationship between ER and PML protein levels. In therapy-sensitive wild-type ER cells with low basal PML1 levels and PI3K/MAPK activity, fulvestrant’s ER-suppressive effects overcome drug-induced elevated PML1 and PI3K/MAPK activity, thereby maintaining therapeutic efficacy. In contrast, in therapy-resistant ER Y537S mutant cells or cells with PML gene amplification, fulvestrant-mediated amplification of constitutively hyperactive PML1-PI3K/MAPK feedback loops dominates over cytotoxic effects, resulting in enhanced cell survival. Notably, reducing PML1 levels through knockdown or arsenic trioxide (ATO), an FDA-approved PML1 degrader, disrupts this resistance circuit and restores endocrine sensitivity. Treatment of ATO resensitizes ER Y537S-bearing resistant tumors to endocrine therapy in xenograft models. These findings establish PML1 as a central hub of resistance, linking ER signaling to the activation of the PI3K/MAPK survival pathway.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
The estrogen receptor (ER or ERα) remains the primary therapeutic target for luminal breast cancer, with current treatments centered on competitive antagonists, receptor downregulators, and aromatase inhibitors. Despite these options, resistance frequently emerges, highlighting the need for alternative targeting strategies. We discovered a novel mechanism of ER inhibition that targets the previously unexplored interface between the DNA-binding domain (DBD) and ligand-binding domain (LBD) of the receptor. Through computational screening and functional assays, we identified mitoxantrone (MTO), an FDA-approved topoisomerase II inhibitor, as a specific ligand for this DBD–LBD interface. Comprehensive biophysical, biochemical, and cellular analyses demonstrate that MTO binding induces distinct conformational changes in the ER, triggering rapid cytoplasmic redistribution and proteasomal degradation through mechanisms independent of its DNA damage activity. Critically, MTO effectively inhibits constitutively active ER mutants (Y537S and D538G) associated with endocrine therapy resistance, suppressing both wild-type and mutant ER-dependent gene expression and tumor growth more potently than fulvestrant in cellular and xenograft models. These findings establish the DBD–LBD interface as a druggable allosteric site that can overcome conventional resistance mechanisms, providing a new therapeutic paradigm for targeting nuclear receptor function through disruption of interdomain communication rather than hormone-binding competition.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
The estrogen receptor (ER or ERα) remains the primary therapeutic target for luminal breast cancer, with current treatments centered on competitive antagonists, receptor downregulators, and aromatase inhibitors. Despite these options, resistance frequently emerges, highlighting the need for alternative targeting strategies. We discovered a novel mechanism of ER inhibition that targets the previously unexplored interface between the DNA-binding domain (DBD) and ligand-binding domain (LBD) of the receptor. Through computational screening and functional assays, we identified mitoxantrone (MTO), an FDA-approved topoisomerase II inhibitor, as a specific ligand for this DBD–LBD interface. Comprehensive biophysical, biochemical, and cellular analyses demonstrate that MTO binding induces distinct conformational changes in the ER, triggering rapid cytoplasmic redistribution and proteasomal degradation through mechanisms independent of its DNA damage activity. Critically, MTO effectively inhibits constitutively active ER mutants (Y537S and D538G) associated with endocrine therapy resistance, suppressing both wild-type and mutant ER-dependent gene expression and tumor growth more potently than fulvestrant in cellular and xenograft models. These findings establish the DBD–LBD interface as a druggable allosteric site that can overcome conventional resistance mechanisms, providing a new therapeutic paradigm for targeting nuclear receptor function through disruption of interdomain communication rather than hormone-binding competition.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 2 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 2: MTO demonstrates enhanced growth inhibition in endocrine-resistant T47D cells
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 2 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 2: MTO demonstrates enhanced growth inhibition in endocrine-resistant T47D cells
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 4 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 4: Evaluation of combination treatment effects between MTO and established ER antagonists in MCF7 cells
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 4 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 4: Evaluation of combination treatment effects between MTO and established ER antagonists in MCF7 cells
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 6 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 6: Comparative pathway analysis reveals distinct transcriptional effects of MTO and fulvestrant
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 6 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 6: Comparative pathway analysis reveals distinct transcriptional effects of MTO and fulvestrant
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 3 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 3: Three-dimensional spheroid growth in MCF7 cells expressing wildtype and mutant ER
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 3 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 3: Three-dimensional spheroid growth in MCF7 cells expressing wildtype and mutant ER
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 7 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 7: Comparative transcriptional pathway analysis of MTO and fulvestrant treatments
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 7 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 7: Comparative transcriptional pathway analysis of MTO and fulvestrant treatments
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Table 1: Analysis of top computational docking candidates from the NIH Clinical Collection
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Table 1: Analysis of top computational docking candidates from the NIH Clinical Collection
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 1 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 1: MTO, unlike fulvestrant, maintains E2-mediated ER-SRC3 interaction
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 1 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 1: MTO, unlike fulvestrant, maintains E2-mediated ER-SRC3 interaction
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 5 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 5: ER protein levels in wild-type and Y537S ER orthotopic xenograft tumors
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 5 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 5: ER protein levels in wild-type and Y537S ER orthotopic xenograft tumors